This article was accepted into the corpus but its outbound wikilinks were never NER-processed — typical at the deepest BFS hop or when the run's entity cap was reached. No expansion funnel to show.
| Eurocat | |
|---|---|
| Name | Eurocat |
| Type | Network of congenital anomaly registries |
| Established | 1979 |
| Region | Europe |
| Headquarters | Leuven, Belgium |
| Parent organization | University of Leuven |
Eurocat Eurocat is a European network of population-based congenital anomaly registries that collects, harmonizes, and disseminates data on birth defects and congenital malformations across multiple European Union member states and neighboring countries. It supports epidemiological research, public health surveillance, and policy by linking registry data to perinatal mortality, prenatal diagnosis, teratogenic exposures, and environmental health inquiries. Operating through standardized protocols and collaborative projects, the network engages academic institutions, public health agencies, and international organizations.
Eurocat coordinates a distributed system of regional and national registries including partners in United Kingdom, Germany, France, Italy, Spain, Netherlands, Belgium, Sweden, Norway, Denmark, Finland, Ireland, Portugal, Greece, Poland, Hungary, Czech Republic, Slovakia, Romania, Bulgaria, Croatia, Slovenia, Lithuania, Latvia, Estonia, Iceland, Switzerland, Austria, Malta, Cyprus, Serbia, Bosnia and Herzegovina, North Macedonia, Albania, Turkey, Russia, Ukraine, Belarus, Moldova, Spain Canary Islands, Reykjavík University, University of Leuven, Karolinska Institutet, University College London, Imperial College London, University of Oxford, University of Cambridge, King's College London, Inserm, Max Planck Society, Robert Koch Institute, Public Health England, European Centre for Disease Prevention and Control, World Health Organization, UNICEF, European Commission, Council of Europe, European Medicines Agency, European Environment Agency, Organisation for Economic Co-operation and Development, European Monitoring Centre for Drugs and Drug Addiction, International Clearinghouse for Birth Defects Surveillance and Research, Centers for Disease Control and Prevention, National Institutes of Health, European Respiratory Society, European Society of Human Genetics, International Society for Prenatal Diagnosis.
Eurocat was founded in 1979 as an initiative linking registries in response to concerns raised by incidents such as thalidomide-related malformations and growing use of prenatal ultrasound. Early collaborators included researchers from University of Leuven, Karolinska Institutet, Inserm, Imperial College London, and the Robert Koch Institute. Major milestones include harmonization efforts aligned with directives from the European Commission, methodological workshops with the World Health Organization, integration with surveillance activities of the European Centre for Disease Prevention and Control, and expansion during enlargement rounds of the European Union in 2004 and 2007. Eurocat participated in high-profile projects such as surveillance during the Chernobyl disaster aftermath, assessment of Zika virus teratogenicity, and studies connected to COVID-19 maternal–fetal outcomes involving partners like Public Health England and CDC collaborators.
Eurocat uses standardized case definitions and coding schemes linked to ICD-10 classifications and works with clinical sources including neonatal intensive care units, teratology centers, obstetrics departments at institutions such as University College London Hospitals, Karolinska University Hospital, Hôpital Necker-Enfants Malades, and regional health authorities like NHS England and Agence Régionale de Santé. Data collection methods include active case ascertainment, linkage with civil registration, prenatal screening records, and hospital discharge datasets from agencies such as Statistisches Bundesamt (Destatis), INSEE, ISTAT, INE, and Statistics Norway. Quality assurance draws on training from WHO Collaborating Centres, peer review with International Clearinghouse for Birth Defects Surveillance and Research, and statistical techniques promoted by Eurostat and academia (e.g., Harvard School of Public Health, London School of Hygiene & Tropical Medicine).
Eurocat outputs include prevalence estimates, temporal trends, and cluster investigations reported through collaborations with European Journal of Epidemiology, The Lancet, BMJ, Nature Communications, PLOS Medicine, PLoS One, European Journal of Public Health, Human Reproduction, Clinical Genetics, Genetics in Medicine, American Journal of Epidemiology, Pediatrics, Acta Paediatrica, Ultrasound in Obstetrics & Gynecology, Prenatal Diagnosis, Birth Defects Research, Environmental Health Perspectives, and policy briefs for European Commission directorates. Findings have quantified baseline prevalences for anomalies such as neural tube defect, congenital heart defect, cleft lip and palate, Down syndrome, gastroschisis, and identified associations with exposures including maternal diabetes mellitus, anti-epileptic drugs (e.g., valproate), isotretinoin, and environmental contaminants assessed in studies referencing Chernobyl fallout, air pollution episodes monitored by the European Environment Agency, and industrial incidents like Seveso.
Eurocat collaborates with academic partners including Karolinska Institutet, University of Oxford, University of Cambridge, UCL Great Ormond Street Institute of Child Health, Erasmus University Rotterdam, KU Leuven, Université Paris Cité, Heidelberg University, University of Milan, University of Barcelona, Universidad Autónoma de Madrid, University of Warsaw, Jagiellonian University, Charles University, Comenius University, Semmelweis University, Bogomolets National Medical University, and research infrastructures like BBMRI-ERIC, ELIXIR, ERIC-CARDIO, and the European Research Council. It engages with international stakeholders including WHO Regional Office for Europe, UNICEF, European Medicines Agency, European Public Health Alliance, and patient groups such as European Medicines Agency Patient Groups and national charities (e.g., Great Ormond Street Hospital Charity, Fondazione Telethon).
Eurocat evidence has informed regulatory decisions by European Medicines Agency committees, influenced screening recommendations by bodies such as NICE, SFP, and national health ministries, and contributed to guidelines from World Health Organization and UNICEF. Its data support risk assessments used by the European Commission in environmental policy and by ECDC in communicable disease contexts. Public health programs in countries like Sweden, Netherlands, Belgium, Ireland, and Spain have used Eurocat reports to guide prenatal screening, folic acid fortification debates reflected in policies from Food and Drug Administration comparisons, and clinical counseling protocols at centers like Great Ormond Street Hospital.
Critiques of Eurocat focus on heterogeneity among registries rooted in differences in legal frameworks (e.g., laws in France, Germany, Poland, Italy), variable ascertainment completeness across regions, delays in data aggregation, and challenges in integrating genomic data from initiatives like 1000 Genomes Project, UK Biobank, All of Us Research Program, and European Genome-phenome Archive. Other limitations include difficulties harmonizing prenatal termination records across jurisdictions influenced by national laws such as those in Ireland (pre-2018), Spain, and Poland, and constraints on data linkage posed by privacy regulations like the General Data Protection Regulation. Ongoing methodological work addresses statistical power for rare defects, case validation against clinical genetic diagnoses at centers such as Great Ormond Street Hospital and Hospital Sant Joan de Déu, and interoperability with registries in regions covered by WHO or the International Clearinghouse for Birth Defects Surveillance and Research.
Category:Health databases